Dr. Howard Fingert joined ONO PHARMA USA, INC. in September 2022, assuming the role of Vice President, Medical Oncology. In this role, Howard guides early- and late-phase clinical research. 

Howard brings to ONO PHARMA USA, INC. more than 25 years of experience conducting clinical trials in North America, Europe, Japan, and other regions. Prior to joining ONO PHARMA USA, INC., Howard led clinical and regulatory functions from Phase 1 through commercialization at leading biopharmaceutical companies, including Takeda, Pfizer, and EMD Serono. His industry work includes extensive roles in public-private partnerships with the US FDA, US National Cancer Institute, and multi-regional organizations. 

Howard earned his MD from University of Illinois School of Medicine, completed his Oncology-Hematology training at Massachusetts General Hospital, Dana Farber Cancer Institute, and formerly served as Assistant Professor at Harvard Medical School. His publications represent original research in clinical and regulatory sciences, and he has held diverse teaching roles about clinical R&D at Harvard and MIT.